The Law Firm of Lasky & Rifkind, Ltd. Announces Class Action Lawsuit Against Northfield Laboratories, Inc.

Lasky & Rifkind, Ltd., a law firm with offices in New
York and Chicago, announces that a lawsuit has been filed in the
United States District Court for the Northern District of Illinois, on
behalf of persons who purchased or otherwise acquired publicly traded
securities of Northfield Laboratories, Inc. ("Northfield" or the
"Company") (NASDAQ:NFLD) between February 20, 2004 and February 21,
2006, inclusive, (the "Class Period"). The lawsuit was filed against
Northfield and Steven A. Gould ("Defendants").
   If you are a member of this class and wish to view a copy of a
complaint and join this class action, please e-mail us at
[e-mail] and request a copy of the complaint
and a plaintiff certification. If you are a member of the Class, you
may move the Court no later than May 16, 2006 to serve as a lead
plaintiff for the Class. Any member of the purported class may move
the Court to serve as lead plaintiff through counsel of their choice,
or may choose to do nothing and remain an absent class member.
However, if you choose to remain an absent class member, unless and
until a class is certified, you are not represented by counsel.
   The complaint alleges that Defendants violated Sections 10(b) and
20(a) of the Securities Exchange Act of 1934 and Rule 10b-5
promulgated thereunder. Specifically, the complaint alleges that
Defendants issued a series of materially false and misleading
statements regarding the safety of PolyHeme, a blood substitute. More
specifically, the Company failed to disclose negative data from an ANH
study concerning ten patients who had heart attacks within seven days
of taking PolyHeme, and that two of those patients had subsequently
died.
   On February 22, 2006, the Wall Street Journal reported that data
available to the Company from the ANH trial, but not the public,
indicated that ten out of eighty one patients who received PolyHeme
suffered a heart attack within seven days, and two subsequently died.
When this was revealed in the article on February 22, 2006, shares of
Northfield reacted negatively, falling from $12.23 per share to $11.64
per share, or a one-day decline of 5%. Shares have continued to fall
in reaction to an inquiry by Senator Charles E. Grassley, Chairman of
the U.S. Senate Finance Committee, as well as an inquiry by the SEC.
   If you bought Northfield securities between February 20, 2004 and
February 21, 2006, inclusive, and would like to obtain information
about the lawsuit, then you are invited to call [phone] to
speak with an advisor.